Table 1: HDACi combination regimens currently in clinical trials. Partial list of clinical trials evaluating the combination of HDACi with other anticancer agents discussed in this paper (source:,

HDACiOther InterventionTumor Type

Entinostat (SNDX-275)azacitidineleukemia, MDS, colorectal cancer, NSCLC

Mocetinostat (MGCD0103)azacitidineMDS

Panobinostat (LBH589)azacitidineMDS, CML, AML
bortezomibperipheral T cell lymphoma, NK/T cell lymphoma, MM, pancreatic cancer
bortezomib, dexamethasoneMM
decitabineMDS, AML
decitabine, temozolomidemelanoma
radiation therapyprostate cancer, esophageal cancer, head and neck cancer



Valproic acidazacitidineadvanced cancers
azacitidine, ATRAAML, MDS
decitabine, ATRAAML
radiation therapy, bevacizumabchildren with high grade gliomas
radiation therapy, temozolomidehigh grade gliomas, brain tumors

VorinostatazacitidineAML, MDS, DLBCL, lymphoma, MM, NSCLC, Non-Hodgkin's lymphoma
bortezomib, AMG 655lymphoma
bortezomib, dexamethasoneMM
cisplatin, pemetrexed, radiation therapyNSCLC
cisplatin, radiation therapysquamous cell carcinoma
gemtuzumab ozogamicin, azacitidineAML
marizomib (NPI-0052)NSCLC, pancreatic cancer, melanoma, lymphoma
paclitaxel, radiation therapyNSCLC
radiation therapybrain metastases, NSCLC, pancreatic cancer, pelvic cancer
radiation therapy, fluorouracilpancreatic adenocarcinoma

ATRA: all-trans retinoic acid, MM: multiple myeloma, NSCLC: nonsmall cell lung carcinoma, AML: acute myeloid leukemia, CML: chronic myelogenous leukemia, MDS: myelodysplastic syndrome, and DLBCL: Diffuse large B-cell lymphoma.